Ϫ ) is increased in the vessel wall of spontaneously hypertensive rats (SHR) where its blockade potentiates endothelium-dependent vasodilation. The purpose of this study was to determine the role of O 2 Ϫ in the hypertension and renal vasoconstriction of SHR and its interaction with nitric oxide (NO). Baseline mean arterial pressure (MAP) and renal vascular resistance were markedly elevated in SHR (nϭ6) 
H ypertension has been associated with low levels of endogenous antioxidants such as vitamin C. 1 Clinical studies show that intravenous infusion of vitamin C or other antioxidants significantly reduces blood pressure in hypertensive patients. 2, 3 The SHR, a model of essential hypertension, is characterized by increased oxidative stress. Using fluorescence microscopy in vivo, Suzuki et al 4 showed that mesenteric arterioles of the SHR have increased O 2 Ϫ production. Furthermore, Auch-Schwelk et al 5 demonstrated that aortic rings prepared from SHR are more sensitive to O 2 Ϫ than are those from WKY. The enhanced aortic contractions to O 2 Ϫ in SHR were blocked by the O 2 Ϫ scavenger SOD. However, previous studies investigating the importance of endogenously generated oxygen radicals in the regulation of blood pressure in SHR have shown modest or scant results. [6] [7] [8] This may relate to the properties of the O 2 Ϫ scavenger administered: some forms such as allopurinol also simultaneously produce O 2 Ϫ , other forms such as native SOD lack membrane permeability, and CuZn SOD is inactivated by divalent ions found intracellularly. The mechanism for the vasodilatory actions of O 2 Ϫ scavengers seen in in vitro studies remains unclear. Several vascular beds of SHR have impaired endothelium-dependent vasodilation. 9 -12 Gryglewski et al 13 
Group 2: MAP During Constant Tempol Infusion
To determine the dose-response relationship for tempol, MAP was measured during basal conditions and during intravenous infusion of tempol at 1.8, 18, 180, and 1800 mol ⅐ kg Ϫ1 ⅐ h Ϫ1 for 30 minutes in anesthetized WKY (nϭ6) and SHR (nϭ6).
Group 3: MAP During Constant Tempol Infusion-Effect of NO Synthesis Blockade
To determine whether O 2 Ϫ increases MAP through interaction with the NO pathway, the MAP response to tempol was determined in anesthetized SHR (nϭ6) and in SHR pretreated with the NO synthase inhibitor L-NAME (11 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ5). To ensure that any change in the MAP response to tempol in SHR during L-NAME administration was not due solely to an increase in MAP and vascular tone, the protocol was repeated in SHR infused with norepinephrine (31 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ6). In all rats, MAP was measured during basal conditions; during 20 minutes of pretreatment with either saline vehicle, L-NAME, or norepinephrine; and after 30 minutes of constant tempol infusion
).
Group 4: Longer-term Effect of Tempol on MAP
MAP was measured before and after 7 days of tempol. Rats were anesthetized with pentobarbitol sodium (50 mg/kg IP, Abbot Laboratories); the left femoral artery was cannulated with PE-50 tubing and MAP was recorded for 60 minutes. On the following day, tempol was administered at a rate of 1.5 mmol ⅐ kg Ϫ1 ⅐ d Ϫ1 IP for 7 days. On the seventh day of tempol administration, rats were anesthetized and MAP was measured again.
Statistics
All values shown are meanϮSE. ANOVA was used to determine statistical significance in groups 1 and 2. Student's t test was used to determine significance in groups 3 and 4, where the comparison was limited to two observations. PϽ0.05 was considered statistically significant. Figure 1 shows the MAP during baseline conditions and infusion of tempol at 24 and 72 mol/kg in WKY and SHR. Baseline MAP was significantly elevated in SHR compared with WKY (145Ϯ4 versus 118Ϯ3 mm Hg, respectively; PϽ0.05). Low-dose tempol (24 mol/kg IV) had no effect in either the WKY (114Ϯ5 mm Hg) or SHR (147Ϯ4 mm Hg). However, higher-dose tempol normalized the MAP of the SHR to the level of WKY. Tempol (72 mol/kg IV) significantly (PϽ0.05) decreased MAP by 11% in WKY (96Ϯ6 mm Hg) and by 28% in SHR (104Ϯ9 mm Hg).
Results

Group 1: Renal Hemodynamics and MAP During Tempol Bolus
Figure 2 depicts renal hemodynamics during basal conditions and infusion of tempol at 24 and 72 mol/kg in WKY and SHR. Baseline RBF was similar between groups (WKY, 7.1Ϯ0.7; SHR, 6.8Ϯ1.0 mL/min) and was not affected during tempol (WKY, 6.6Ϯ0.7; SHR, 6.7Ϯ0.8 mL/min). In contrast, baseline RVR was significantly increased in SHR compared with WKY (24Ϯ3 versus 17Ϯ1 mm Hg ⅐ mL Ϫ1 ⅐ min Ϫ1 , respectively; PϽ0.05). Low-dose tempol had no effect on ). Figure 3 illustrates the dose-response relationship between tempol at 1. Figure 4 illustrates the percent change in MAP in SHR pretreated with isotonic saline vehicle (2 mL/h IV) or the NO synthesis inhibitor L-NAME (11 mol ⅐ kg Ϫ1 ⅐ h Ϫ1 IV). As in the previous group, infusion of tempol (180 mol ⅐ kg Ϫ1 ⅐ min
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Ϫ1
) for 30 minutes significantly decreased MAP by 32% in SHR (121Ϯ17 mm Hg, PϽ0.05). In marked contrast, the NO synthesis inhibitor L-NAME abolished the MAP response to tempol. Twenty minutes of L-NAME infusion alone increased MAP by 18% from 158Ϯ11 to 187Ϯ8 mm Hg, and MAP remained unchanged during tempol infusion (186Ϯ4 mm Hg). Time control studies in a separate group of SHR showed that MAP remained steady during L-NAME infusion (change in MAP at 50 minutes, 0.3Ϯ3.3%; NS). To investigate whether the failure of tempol to lower MAP in L-NAME-infused rats was a consequence of the severe vasoconstriction and hypertension, the protocol was repeated in SHR infused with norepinephrine (31 nmol
) in place of L-NAME. Norepinephrine increased MAP by 15% from 164Ϯ4 to 188Ϯ7 mm Hg. This was similar to the increase with L-NAME. However, tempol significantly decreased MAP by 14% (161Ϯ7 mm Hg, PϽ0.05) in SHR infused with norepinephrine. Time-control studies in a separate group of SHR showed that MAP remained steady during norepinephrine infusion (change in MAP at 50 minutes, 2.0Ϯ0.0%; NS). Figure 5 depicts the change in MAP after 7 days of tempol administration in WKY and SHR. Baseline MAP was significantly (PϽ0.05) elevated in SHR (133Ϯ2 mm Hg) compared with WKY (96Ϯ1 mm Hg) but was lower than in previous groups, probably because a different anesthesia was used. After 7 days of tempol (1.5 mmol ⅐ kg Ϫ1 ⅐ d Ϫ1 IP), there was no change in MAP of the WKY (97Ϯ1 mm Hg). In contrast, tempol significantly reduced MAP of the SHR by 10% to 120Ϯ4 mm Hg (PϽ0.05).
Group 4: Longer-term Effect of Tempol on MAP
Discussion
Both the blood pressure and the renal vasculature of the SHR have an increased responsiveness and sensitivity to the vasodilation produced by scavenging of O 2 Ϫ . Tempol, a membrane-permeable SOD mimetic, normalized MAP and RVR of SHR. Because the antihypertensive response was blocked by NO synthesis inhibition, it must depend on NO. O 2 Ϫ also appears to be important in the longer-term control of blood pressure in SHR. These results suggest that SHR have increased O 2 Ϫ activity that contributes to their hypertension. In these studies, the effect of tempol on RVR may have been secondary to its effect on blood pressure with engagement of renal autoregulation. O 2 Ϫ is generated and acts both extracellularly and intracellularly, where it can have harmful effects including lipid peroxidation, protein aggregation, and DNA destruction. 25 Previous investigators have used scavengers of O 2 Ϫ to reduce inflammation, 26 atherosclerosis, 27 and ischemia/reperfusion injury. 28 Because native SOD has limited membrane permeability and has proved to be disappointing in preventing adverse effects of O 2 Ϫ or in reducing blood pressure in vivo, 8 alternative agents with SOD-like activity have been investigated. However, some SOD mimetics such as CuZn SOD are metal dependent and can become ineffective intracellularly because of metal-ligand dissociation. Therefore, compounds with SOD-like activity having low molecular weight, biological stability, no toxicity, and membrane permeability are preferred for use in vivo. Mitchell et al 29 have shown that tempol is a low-molecular-weight, stable SOD mimetic that is metal independent and cell membrane permeable. Tempol does not act as a catalase mimetic or alter hydrogen peroxide concentration, 30 and tempol does not bind NO or produce O 2 Ϫ . 31 These findings suggest that tempol is specific to the superoxide radical. Tempol prevents O 2 Ϫ -induced damage during inflammation, 20 radiation, [21] [22] [23] and cardiac reperfusion injury 19 and protects cardiac myocytes from ischemic damage. 31 Previous studies investigating the short-term actions of O 2 Ϫ on blood pressure in SHR demonstrated that bolus injection of a xanthine oxidase inhibitor to block the formation of O 2 Ϫ from xanthine 7 or CuZn SOD 8 acutely decreased MAP in the SHR; however, results for WKY were not reported. Therefore, we compared the effect of scavenging O 2 Ϫ on MAP in SHR to their genetic control WKY. We show that acute tempol administration normalized MAP and RVR in SHR to the level of WKY. In addition, 7 days of tempol administration reduced MAP by 10% in SHR, whereas it had no effect in WKY. This last result confirms the finding that long-term administration of another O 2 Ϫ scavenger, vitamin C, reduces blood pressure in SHR. 6 Our data show that O 2 Ϫ is increased selectively in SHR compared with the normotensive control, which did not have any response to 7 days of tempol administration. The data also show that acute tempol administration had a stronger blood pressure-lowering effect than 7-day treatment. The disparity between the results may be due to the route and dose of administration of tempol. Previous investigators showed that intraperitoneal tempol administration in mice yields a peak blood concentration (600 g/mL) in 5 to 10 minutes, after which the concentration rapidly declines with a half-life of 2 hours. 22 We chose the 7-day dose of tempol because higher doses given intraperitoneally increase mortality.
Earlier studies have established a role for O 2 Ϫ in the aorta 5, 7, 16 and mesenteric arterioles 4 of SHR. However, the kidneys play an important role in the development and maintenance of hypertension. Tempol vasodilated the renal vasculature in SHR more than in WKY. Under control conditions, RVR was significantly elevated in SHR, and tempol normalized RVR in SHR to the level of WKY. Because tempol reduced MAP without changing RBF, renal vasodilation was inferred. The RVR response to tempol may be a result of RBF autoregulation. Whether tempol directly or indirectly decreases RVR in SHR remains to be further elucidated.
The mechanism of the selective reduction in blood pressure by scavenging of O 2 Ϫ is unclear. One possible explanation may be that O 2 Ϫ can inactivate NO and thereby blunt the vasodilation pathway. Several studies have shown that blockade of NO causes hypertension in animal models 32, 33 and humans. 34 SHR have reduced endothelium-dependent vasodilation in several vascular beds, including the kidney, 10 -12,35 that has been ascribed in part to increased NO degradation by O 2 Ϫ . Tschudi et al 15 demonstrated that the defective release of NO from mesenteric arterioles of SHR could be normalized after SOD. Grunfeld et al 16 showed that endothelial cells cultured from aorta of stroke-prone SHR had an apparent decrease in NO release that was fully reversed by SOD and therefore presumably represented enhanced NO degradation by O 2 Ϫ . In their study, blockade of SOD enhanced endothelium-dependent relaxation of the aorta of SHR to a greater extent than in WKY. Our data demonstrate that intravenous infusion of tempol decreases MAP by 32% in SHR and that this response is blocked in SHR pretreated with the NO synthase inhibitor L-NAME. To ensure that the negative response to tempol during L-NAME was not merely due to an increase in systemic vascular resistance and blood pressure, we examined the MAP response to tempol in SHR infused with norepinephrine. In SHR pretreated with norepinephrine, which produced a similar increase in MAP, tempol reduced MAP by 14%. Previous investigators have shown that catecholamines, including norepinephrine, have antioxidant properties. 36 Because norepinephrine is an antioxidant, the addition of another antioxidant would be less effective. For this reason, tempol may have been less effective in lowering MAP in SHR pretreated with norepinephrine (14%) than in normal SHR (32%). Overall, these data suggest that NO plays an important role in mediating the antihypertensive actions of scavenging of O 2 Ϫ . There are several possible mechanisms by which NO mediates the antihypertensive actions of tempol. First, tempol may directly donate NO. This possible mechanism has been proven incorrect because tempol does not decompose to NO. 37 Second, scavenging of O 2 Ϫ increases the half-life of NO. Gryglewski et al 13 showed that O 2 Ϫ is important in the breakdown of NO to peroxynitrite, and Rubanyi and Vanhoutte 14 demonstrated that O 2 Ϫ inactivates NO in coronary artery rings. There are several possible sources of O 2 Ϫ , including xanthine oxidase, NADPH oxidase, incomplete electron transport, and even brain NO synthase. 30 The source of O 2 Ϫ in our study remains unclear. However, because previous studies suggest a role for O 2 Ϫ released from the vasculature in SHR, brain NO synthase does not appear to be the major source. As a result of the powerful interaction between O 2 Ϫ and NO, tempol may prolong the half-life of NO and thus allow it to exert a more powerful vasodilatory action. Finally, by blocking the formation of peroxynitrite, tempol may inhibit the production of vasoconstrictor endoperoxides that are stimulated by peroxynitrite in macrophages. 38 In summary, short-and longer-term administration of the stable, membrane-permeable SOD mimetic tempol significantly reduces MAP in SHR to a greater extent than in WKY. Tempol also significantly reduced RVR in SHR. Whether this decrease was due to a direct action on renal vessels or an autoregulatory response to changes in renal perfusion pressure remains to be determined. Overall, this is the first study showing that scavenging of O 2 Ϫ both extracellularly and intracellularly with a membrane-permeable SOD mimetic normalizes the RVR and MAP of SHR. The antihypertensive actions of tempol are dependent on NO. Whether scavenging of O 2 Ϫ decreases MAP through direct or indirect action on the L-arginine/NO pathway requires further investigation.
